Abbott Laboratories (ABT) Capital Expenditures (2009 - 2026)

Abbott Laboratories has disclosed Capital Expenditures across 18 years of filings, most recently posting $497.0 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 1.0% year-over-year to $497.0 million; the TTM figure through Jun 2026 stood at $2.1 billion (down 8.0% YoY), while the FY2025 annual figure was $2.2 billion, down 1.63% from the prior year.
• Capital Expenditures came in at $497.0 million for Q2 2026 at Abbott Laboratories, up from $399.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $755.0 million in Q4 2023 to a low of $321.0 million in Q1 2022.
• Average Capital Expenditures over 5 years is $514.1 million, with a median of $499.5 million recorded in 2025.
• Year-over-year, Capital Expenditures retreated 19.14% in 2022 and soared 33.77% in 2023.
• Over 5 years, Capital Expenditures stood at $610.0 million in 2022, then rose by 23.77% to $755.0 million in 2023, then fell by 4.64% to $720.0 million in 2024, then slipped by 4.31% to $689.0 million in 2025, then decreased by 27.87% to $497.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $497.0 million in Q2 2026, $399.0 million in Q1 2026, and $689.0 million in Q4 2025.